Create Your Account

Leave blank

Questions? Call 1(877) 440-9464

Amicus Therapeutics, Inc. Reports Q4 EPS of $(0.20) vs $(0.37) Est
March 25, 2013 03:39pm

On March 12, 2013 at 5:06:57 am EST, Benzinga published that Amicus Therapeutics, Inc. (NASDAQ: FOLD) reported Q4 EPS of $(0.20) versus the estimated $(0.37), beating by $0.17. EPS were Up 20% from the same quarter last year.

Canaccord Genuity Upgrades Venaxis to Buy; FDA Approval on Track for 2014
February 25, 2013 04:33pm

At 6:46 AM EST on February 25, 2013, Benzinga Pro reported the following news on Venaxis (NASDAQ: APPY) from a research report from Canaccord Genuity.

In the report, Canaccord Genuity noted, "In our opinion, Venaxis (formerly AspenBio Pharma) is on track for FDA approval of the first blood test aiding in identifying patients at low risk for appendicitis. … Venaxis recently began its pivotal trial (2,000 patients; 28 sites), and expects to complete the study by August-September 2013, with FDA submission in Q4/13. We estimate FDA approval sometime prior to mid-2014."

Venaxis opened at $2.14, reach a high of $2.65 and closed at $2.40 for a gain of 12.15 percent.

Virginia Commerce Bancorp Initiates Formal Review of Strategic Alternatives, Stock Surges 10.24%
January 15, 2013 03:21pm

At 6:08:42 AM on 1/14/13, Benzinga Pro reported the following on Virginia Commerce Bancorp (NYSE: VCBI), which surged 10.24 percent to $11.80 during trading:

Virginia Commerce Bancorp (NASDAQ: VCBI) today announced that its Board of Directors has initiated a formal review of strategic alternatives to enhance shareholder value, including a possible merger, sale or other form of business combination. The Company has retained Sandler O'Neill + Partners, L.P. as financial advisors to advise the Board of Directors in its review. The Company has not set a definitive timetable for completion of its evaluation and there can be no assurance that this process will lead to the pursuit, approval or completion of any transaction or other strategic initiative.

BMO Capital Upgrades Halozyme Therapeutics to Outperform and Raises PT to $12.00, Stock Surges 14.98%
January 15, 2013 03:18pm

At 7:52:36 AM on 1/14/13, Benzinga Pro reported BMO Capital's upgrade of Halozyme Therapeutics (NYSE: HALO) from Market Perform to Outperform and raised its's price target to $12.00 per share. During trading, the stock rose to $8.35, a surge of 14.98 percent.

Stifel Nicolaus Upgrades Crimson Exploration to Buy with $3.75 PT, Stock Surges 10.71%
January 15, 2013 03:14pm

At 8:10:37 AM on 1/14/13, Benzinga Pro posted the upgrade of Crimson Exploration (NYSE: CXPO) from Hold to Buy at Stifel Nicolaus with a $3.75 PT. The stock reached a high of $3.16, a surge of 10.71 percent.